Bringing medicine back to life?

Discover how Orfenix’ Vincent van der Wel reimagines existing drugs and navigates complex business landscapes with Orfenix, making treatments affordable and ensuring patients receive the care they need without high costs.

What We Do.

We turn great ideas into accessible medicines. To do that we work with academics to turn their ideas into reality and in a societally responsible manner. For us, this means building a sustainable business while ensuring patient access. Explore our portfolio to see how we realize that ambition.

Reformulating For Cystinosis

Repurposing For PXE

Repurposing For VWM

Academic Partners.

Insights.

Mastering EMA Briefing Documents: Essential Tips and Tricks

The European Medicines Agency (EMA) scientific advice procedure is designed to enhance communication between sponsors and regulators, streamlining the development of high-quality medicinal products. Preparing a clear and well-structured briefing document is key to obtaining meaningful feedback. This document includes the product’s development program, precise questions for advice, and evidence-backed applicant position statements that consider alternative approaches and proactively address potential concerns.

read more

Planning for access – Socially Responsible Licensing

Orfenix welcomes a recently published report of the Medicines Patent Pool, in partnership with Boston Consulting Group, shows how voluntary licensing brings both improved access to medicines, in particular in low and middle-income countries and economic benefits to the companies doing the out-licensing.

read more

Contact Orfenix.

For more information or to explore partnership opportunities, feel free to reach out to us anytime!

Follow us on LinkedIn

Meet the team